The ryanodine receptor (RyR2) is an intracellular Ca 2+ release channel essential for cardiac excitation-contraction coupling. Abnormal RyR2 channel function results in the generation of arrhythmias and sudden cardiac death. The present study was undertaken to investigate the mechanistic basis of RyR2 dysfunction in inherited arrhythmogenic cardiac disease.
Introduction
The cardiac ryanodine receptor (RyR2) is a key component of excitation-contraction coupling, mediating rapid Ca 2+ release from the sarcoplasmic reticulum (SR). RyR2 channels are closed in the muscle relaxation phase, whereas inappropriate SR Ca 2+ release causes deleterious effects on cardiac function. Indeed, RyR2 dysfunction leading to diastolic SR Ca 2+ leak has been associated with both genetic and acquired cardiac disorders. 1 -4 Mutations in the RyR2 gene, inherited in an autosomal dominant fashion, have been linked to two diseases displaying overlapping clinical phenotypes: catecholaminergic polymorphic ventricular tachycardia (CPVT1) and arrhythmogenic right ventricular dysplasia (ARVD2). Both disorders are associated with episodes of potentially lethal arrhythmias triggered by emotional or physical stress and exhibit a mortality rate of 30%. CPVT1/ARVD2 exhibits incomplete penetrance, that is, carriers of the same mutation display differences in the severity of symptoms and some remain completely asymptomatic indicating the involvement of other factors or compensatory mechanisms. The CPVT1 phenotype is manifested in the absence of structural abnormalities, whereas ARVD2 is associated with progressive degeneration and fibrofatty replacement of the right ventricular myocardium. 5, 6 The two disorders may represent a variable phenotype of the same disease, because the same mutation has been described as causative of both CPVT1 and ARVD2 in different patients. 6 -8 To date, around 150 arrhythmia-associated RyR2 mutations have been reported, the vast majority of which are missense (http://www. fsm.it/cardmoc/, 13 November 2014). RyR2 mutations tend to cluster in three distinct regions: the N-terminus, a small central domain, and a large C-terminal region. Most of the mutations studied induce gainof-function changes in RyR2, reflected by an increased sensitivity to activation by physiological and pharmacological agonists including Ca 2+ , caffeine, and cAMP-mobilizing agents. 9 -15 Reduction and lossof-function RyR2 mutations causative of CPVT1/ARVD2 have also been described. 13, 16 This is reminiscent of central core disease, where most RyR1 mutations are gain-of-function, but a few loss-of-function, mutants have also been reported. 17, 18 Different molecular mechanism(s) underlying RyR2 channel deregulation have been proposed, including abnormal binding of FKBP12. 6, 12, 15 reduced threshold for store overload-induced Ca 2+ release, 10, 19 and defective inter-domain interactions. 14, 20 Although there are conflicting reports for a given mutation that could be down to methodological differences, it is possible that there is no single unifying hypothesis, with each RyR2 mutation differentially affecting the diverse channel regulation mechanisms. RyRs are the largest ion channels known, composed of four identical subunits of 5000 amino acids. The C-terminal part contains the transmembrane domains that form a Ca 2+ -conducting pore and is also believed to comprise the primary tetramerization determinant. 21 -25 The large cytoplasmic N-terminal portion is required for regulation of the pore and serves as a scaffold for accessory proteins, ions, and other modulators. 26 Communication of the stimulatory/inhibitory cytoplasmic signals to the channel pore is conveyed by long-range conformation changes and interactions between structural and functional domains. Recently, we identified a novel N-terminus intersubunit interaction within RyR2, which is conserved in mammalian RyR isoforms and the related inositol trisphosphate receptor. 27, 28 We further presented functional evidence, suggesting that RyR2 N-terminus tetramerization is involved in the stabilization of the closed state of the channel.
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Given that the N-terminus is one of the three mutation hot spots, we speculated that arrhythmia-linked mutations may have an effect on N-terminus self-association and RyR2 channel function. In this study, we find that a single missense mutation (L433P) has a profound effect on tetramerization of both the isolated N-terminus domain and the fulllength protein. Functional assays further demonstrate that the RyR2 L433P channel is unstable, and it also displays altered Ca 2+ dependence and compromised channel closure. Remarkably, dantrolene, a drug used to treat the RyR1-mediated neuromuscular disorder malignant hyperthermia (MH), has the ability to reverse the mutation-induced phenotype.
Methods
A detailed description is available in Supplementary Material online on the Cardiovascular Research website. Unless otherwise stated, cumulative data were derived from at least three independent experiments.
Yeast two-hybrid, co-immunoprecipitation, and chemical cross-linking assays
Yeast two-hybrid (Y2H), co-immunoprecipitation (co-IP), and chemical cross-linking assays were carried out as described in Zissimopoulos et al. 27, 28 For the experiments performed to test the effect of dantrolene, cell homogenates were incubated with 1 mM dantrolene for 1 h at 378C prior to cross-linking. The optical density of relevant bands was determined by densitometry using a GS-700 scanner (Bio-Rad) and the Quantity One software (Bio-Rad). Statistical analysis was carried out using the GraphPad Prism software; one-way ANOVA with Bonferroni post hoc test for ambient conditions, Kruskal -Wallis test with Dunn's post hoc test was used for group comparison with unequal variance (P , 0.05 in Bartlett's test) for reducing conditions.
Sucrose density gradient centrifugation
Sucrose density gradient centrifugation was carried out as previously described. 28 For the experiments performed to test the effect of dantrolene, all buffers were supplemented with dantrolene at 1 mM. Densitometry analysis was performed and the amount of RyR2 in each fraction was normalized against the amount of input protein in the microsomes. ]ryanodine-binding assays were performed as previously described. 28 For the experiments to test the effect of dantrolene, samples were preincubated in the presence of 1 mM dantrolene for 1 h at room temperature. Sigmoidal dose-response curve fitting (four-parameter logistic equation with bottom and top constrained to 0 and 100, respectively) and statistical analysis were performed using the GraphPad Prism software. 
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Results
The L433P mutation disrupts RyR2 N-terminus self-association
To test the effect of the L433P mutation on RyR2 N-terminus selfassociation, we employed the Y2H system reporting on proteinprotein interactions in a living cell. The RyR2 N-terminus domain (1-906 amino acids) was expressed in yeast as a fusion with GAL4 AD (AD4L constructs) or with DNA-BD (BT4L constructs). The interaction of the WT fragment with itself (BT4L WT + AD4L WT ) was very strong, as previously reported. 28 Quantitative liquid b-galactosidase assays indicated that the presence of the L433P mutation severely compromises RyR2 N-terminus self-interaction in situ ( Figure 1A ). Figure 1B) ; however, the amount of the recovered mutant fragment is substantially lower than that of its WT counterpart. Quantification using densitometry analysis (n ¼ 5) of the amount of BT4L L433P or BT4L WT recovered in the AD4L WT immunoprecipitate indicates that the presence of the L433P substitution in the RyR2 N-terminus reduces its ability to interact with the WT fragment by 60% ( Figure 1B ).
Dantrolene enhances RyR2
L433P N-terminus tetramerization Figure 2A and D), in agreement with our previous report. 28 Chemical cross-linking of the BT4L L433P mutant fragment resulted in the appearance of the tetramer; however, its abundance was rather low relative to WT ( Figure 2B and E). Cumulative data (n ≥ 6) following densitometry analysis demonstrated that the presence of the L433P mutation resulted in an 60% decrease in the tetramer-to-monomer ratio ( Figure 2G , 60 min). This effect was also seen under reducing conditions, where dithiothreitol (DTT, 10 mM) was used prior to chemical cross-linking to reduce the endogenous disulfide bonds that covalently link BT4L tetramers. Following DTT pre-treatment, the tetramer-to-monomer ratio for BT4L L433P was decreased by 60% compared with the WT fragment ( Figure 2H , 60 min).
Dantrolene is a drug used for the treatment of the RyR1-mediated neuromuscular disorder MH, 29 and despite having no effect on WT RyR2, 30 dantrolene was reported to restore normal cardiac function in RyR2-related cardiac disease. 14,31 -34 Since its putative binding site is contained within the RyR2 N-terminus (residues 601-620, identical to RyR1 residues 590-609), 35, 36 we investigated the effects of dantrolene on RyR2 N-terminus oligomerization. BT4L WT and BT4L
L433P
, expressed in mammalian HEK293 cells, were treated with 1 mM dantrolene prior to chemical cross-linking and analysed by western blotting. Dantrolene treatment did not produce any appreciable effect on BT4L
WT tetramer formation (see Supplementary material online, Figure S1 ). Remarkably, dantrolene induced a substantial increase in BT4L L433P tetramer formation under both ambient and reducing conditions ( Figure 2C and F ). Cumulative data (n ≥ 6) following densitometry analysis revealed that the drug increased the tetramer-to-monomer ratio by approximately two-fold ( Figure 2G and H, 60 min). These findings suggest that dantrolene is able to partially reverse the L433P mutation-induced defect in N-terminus self-association.
The L433P mutation results in unstable RyR2 tetrameric channels
The Y2H, co-IP, and chemical cross-linking experiments described above indicate that the L433P mutation significantly impairs the ability of the RyR2 N-terminus to form tetramers, but this remained to be determined for the full-length protein.
To test this, RyR2 oligomerization was assessed by sucrose density gradient centrifugation of CHAPSsolubilized HEK293 microsomes expressing the WT or mutant protein.
This technique separates proteins according to their size under nondenaturing conditions, therefore allowing for non-covalent proteinprotein interactions to be retained. Western blot analysis of density gradient fractions indicated that solubilized RyR2 WT was almost exclusively present in 'heavy' sucrose fractions ( Figure 3A) , a sedimentation profile consistent with the known tetrameric assembly of the channel, whereas minimal monomer was detected in 'light' fractions. Notably, the distribution of RyR2 L433P was considerably different from RyR2 WT , with the mutant protein widely distributed over almost the entire sucrose gradient ( Figure 3B ). Some RyR2 L433P protein was indeed detected in 'heavy' fractions (25-28%) corresponding to the tetramer, but the mutant was enriched in 'light' sucrose fractions (15-17%) corresponding to dissociated subunits. Quantification using densitometry analysis (n ≥ 3) demonstrates that RyR2 L433P forms substantially less tetramers compared with RyR2 WT (P , 0.05; Figure 3D and see
Supplementary material online, Figure S2 Figure S3 ). Given that high-affinity ryanodine binding requires an intact tetrameric RyR2 channel, 37 the most plausible explanation is that the RyR2 L433P tetramer assembly is partially impaired, which is consistent with the density gradient centrifugation profile. We subsequently tested whether dantrolene treatment affects tetramer stability of the full-length RyR2
L433P
. Using sucrose density gradient centrifugation, we found that dantrolene results in substantial redistribution of the RyR2 L433P sedimentation profile, with most of the protein enriched in 'heavy' sucrose fractions resembling the RyR2 WT pattern ( Figure 3C ). Cumulative data (n ≥ 3) indicated that dantrolene shifted the abundance of the RyR2 L433P protein from 'light' sucrose fractions to predominantly 'heavy' fractions, similar to RyR2 WT ( Figure 3D and see Supplementary material online, Figure S2 ). These findings suggest that dantrolene promotes tetramer stability of full-length RyR2
. Dantrolene (1 mM) also resulted in a substantial ( 50%) increase in [ ; monomer (M) and tetramer (T) are indicated with the arrows. Densitometry analysis (n ≥ 6) was carried out on the bands corresponding to tetramer and monomer moieties, and used to calculate tetramer formation at (G) ambient or (H ) reducing conditions. Data are given as mean value + SEM; statistical analysis was carried out using one-way ANOVA with the Bonferroni post hoc test (G) or non-parametric (Kruskal-Wallis) test with Dunn's post hoc test (H ).
Defective RyR2
L433P N-terminus self-association underlies altered Ca 21 sensitivity To obtain some insights into the functional effects of the L433P mutation, we tested the Ca 2+ dependence of the mutant channel using . Western blot analysis of subcellular HEK293 fractions showed that BT4L is expressed at similar levels when co-expressed with the full-length RyR2 L433P or RyR2 WT (see Supplementary material online, Figure S4 ). However, the amount of BT4L detected in the microsomal fraction was lower upon co-expression with RyR2 L433P than with RyR2 WT , despite comparable RyR2 protein levels, indicating reduced BT4L interaction with the mutant channel relative to WT. This is entirely compatible with our Y2H and co-IP assays on the isolated N-terminal fragments, described above. Figure 4D ). Thus, contrary to WT, the mutant L433P channel is not affected by BT4L, an observation that is most probably due to the N-terminal self-association within RyR2 L433P already being disrupted. 
Discussion
In the present study, we investigated the molecular mechanism underlying RyR2 channel dysfunction in arrhythmogenic cardiac disease. Our major findings are: (i) the arrhythmogenic L433P mutation compromises RyR2 N-terminus self-association resulting in defective channel closure and (ii) dantrolene promotes N-terminus self-association thereby restoring RyR2 L433P channel function. 
The N-terminus domain is an important structural determinant for RyR2 tetramerization
Using independent but complementary experimental techniques, we found that the L433P mutation results in substantially reduced selfassociation of the human RyR2 N-terminus domain (Figures 1 and 2 ). This mutation cannot affect intersubunit interactions directly, because it is buried within the three-dimensional structure of the RyR2 N-terminus. 38 In particular, L433 lies within an a-helix, and its substitution for proline, a rigid body amino acid, is likely to disrupt the helix and alter the structure locally. This may in turn induce allosteric rearrangements within the RyR2 N-terminus, indirectly affecting the intersubunit interface, as suggested for some RyR1 mutations. 39 Moreover, density gradient centrifugation indicated that the full-length RyR2 L433P has reduced tetramer stability ( Figure 3) . This is further supported by measurements of maximal [ , which was substantially decreased compared with WT (despite equivalent protein amounts). It is generally believed that the C-terminal region is necessary and sufficient for oligomerization of the native RyR. This is based on observations that large RyR1/2 C-terminal fragments containing the transmembrane domains are able to form a Ca 2+ -conducting pore and bind ryanodine, 21, 22, 24, 25 whereas the extreme cytoplasmic C-terminal tail is capable of tetramerization. 40 In addition, RyR1 lacking the last 15 amino acids does not display high-affinity ryanodine binding, an effect attributed to impaired tetrameric assembly. 23 Recently,
we have reported that the N-terminus of all three mammalian RyR isoforms is also capable of tetramerization. 27, 28 The present study demonstrates that the arrhythmia-linked L433P mutation disturbs the tetramerization of not only the RyR N-terminus, but also the full-length protein. Although we cannot exclude the possibility of long-range alterations affecting C-terminal domain organization, the most likely explanation is that the N-terminus selfassociation is a significant RyR oligomerization determinant contributing to the tetrameric stability of the protein complex.
Defective N-terminus self-association underpins RyR2 L433P channel deregulation
Our functional studies suggest that defective N-terminus self-association within the L433P mutant channel results in increased Ca 2+ sensitivity (Figure 4) . Exogenous N-terminus domain (BT4L) was previously shown to enhance native RyR2 [ 3 H]ryanodine binding at low Ca 2+ concentrations most likely due to disruption of endogenous RyR2 N-terminal intersubunit interactions. 28 This was also found in the current study with BT4L WT lowering the EC 50 for Ca 2+ activation of RyR2 WT ( Figure 4C ). store content were observed ( Figure 5) , concurs with the transgenic mouse model. Based on these findings, we propose a model where the arrhythmia-linked L433P mutation impairs N-terminal intersubunit interactions resulting in defective channel closure ( Figure 6 ).
Our findings indicate that the functional defect produced by the L433P mutation is two-fold: (i) reduced number of functional channels and (ii) increased Ca 2+ sensitivity. The interplay between these two empirical observations, which could have seemingly opposite effects, namely depressed or enhanced Ca 2+ mobilization, may explain the distinctive Ca 2+ release profile previously reported for RyR2 L433P and also observed in the present study. Thomas et al. 13 reported that, unlike other CPVT1/ARVD2 mutations, RyR2 L433P has reduced caffeine sensitivity, which could be due to the reduced number of functional channels ( Figure 3) . On the other hand, they also found that, similar to other mutations, RyR2 L433P channels result in increased Ca 2+ release rate and prolonged Ca 2+ transient, 13 which could be due to enhanced Ca 2+ sensitivity ( Figure 4) . We note that prolonged Ca 2+ transients were also observed in the present study ( Figure 5 ), where Ca 2+ mobilization was induced by Ca 2+ store overload instead of caffeine application.
The L433P mutation has also been functionally characterized by an independent group, which reported increased propensity for spontaneous Ca 2+ oscillations due to enhanced luminal Ca 2+ activation, similar to other RyR2 mutations. 10 Jiang et al. 10 also reported no change in cytoplasmic Ca 2+ activation for RyR2
L433P
, in disagreement with our results. The reason for these discrepancies is unclear since we used the same expression system (HEK293 cells) and functional assays Figure S5 ), which form a flexible loop connecting two a-helices, 38 and this disparity could therefore result in local structural differences. Importantly, our present work identifies the putative mechanism underlying RyR2 L433P channel dysfunction, namely defective N-terminal intersubunit interactions. This molecular defect is functionally manifested as perturbed cellular Ca 2+ handling with unique characteristics ( Figure 5 ). 
Dantrolene reverses the L433P mutation-induced impairment and restores channel function
Remarkably, we found that dantrolene was able to enhance the tetramer formation of the L433P mutant RyR2 N-terminus domain ( Figure 2 ) and improve the tetrameric stability of the full-length mutant protein ( Figure 3) . Moreover, dantrolene was found to normalize the abnormal Ca 2+ mobilization pattern in cells expressing RyR2 L433P ( Figure 5 ). Dantrolene was synthesized in 1967 as a new class of skeletal muscle relaxant and since 1977 has been widely used to treat MH, a pharmacogenetic disorder associated predominantly with RyR1 mutations. 29 Although dantrolene inhibits RyR1 channel activity, it has no effect on RyR2 either in native cardiomyocytes or when heterologously expressed in HEK293 cells. 30 The drug-binding site has been mapped to residues 590-609 within RyR1, which are identical to RyR2 residues 601-620; yet the WT RyR2 surprisingly does not bind dantrolene. 35, 36 However, a number of recent studies reported that dantrolene prevents the SR Ca 2+ leak mediated from dysfunctional RyR2, 14,31 -34 in agreement with our present findings ( Figure 5) .
Collectively, these studies suggest that the dantrolene-binding site only becomes accessible in the altered RyR2 conformation presented in genetic or acquired cardiac disease. It was previously postulated that the drug's mechanism of action involves stabilization of inter-domain interactions between the N-terminal and central regions of RyR. 14, 32, 33, 42 However, a recent study reported that the location of the dantrolene-binding site is distal to the RyR2 central region, and it was suggested that dantrolene may allosterically modulate the interaction between the N-terminal and central domains. 43 In light of our present observation of direct effects on RyR2 N-terminus self-association, we propose that dantrolene's therapeutic effect is mediated by the restoration of the compromised N-terminal intersubunit interactions within arrhythmogenic mutant RyR2 ( Figure 6 ). We should note that dantrolene was used in our studies at 1 mM, a clinically relevant concentration since this drug reaches a plasma concentration of 4.2 mg/L ( 12 mM) in MH patients. 29 Dantrolene has not been associated with any deleterious effects on cardiac contractility, and while its use is only temporary in MH, it is chronically administered for the treatment of skeletal muscle spasticity. The fact that dantrolene does not alter normal RyR2 and cardiac function, but affects only the diseased heart, is of particular importance for its potential clinical application to attenuate arrhythmias.
Implications for CPVT/ARVD and heart failure
Abnormal RyR2 channel regulation results in arrhythmias and has been implicated in inherited (CPVT1/ARVD2) and acquired cardiac diseases (heart failure). 32, 34 Thus, we propose that defective N-terminal intersubunit interactions may be integral to the molecular mechanism underlying RyR2 channel deregulation in both genetic and acquired arrhythmogenic cardiac disease. At present, it is unclear how a RyR2 mutation can lead to right ventricle degeneration. Arrhythmogenic right ventricular cardiomyopathy or dysplasia has been described as a disease of the desmosome, because it is associated predominantly with mutations in desmosomal proteins. 47 -49 ARVD has incomplete penetrance and highly variable clinical manifestation, indicating that there is not a straightforward genotype-phenotype relationship. Arrhythmias can also appear early in the disease before significant structural remodelling of the myocardium and contractile dysfunction develop. Several mechanisms have been proposed to explain the development of right ventricle dysfunction and fibrofatty scar formation, including disruption of cell-cell adhesion, gene transcription involved in adipogenesis, and cardiomyocyte apoptosis. Perturbed Ca 2+ handling due to dysregulated RyR2 leads to apoptosis and cell loss, 50 providing a potential explanation for the development of ARVD by the RyR2 L433P mutation. It should be noted that a RyR2 L433P mouse knock-in model was recently generated, and while it was found to display the CPVT phenotype (as well as atrial fibrillation), the heart did not present any structural abnormalities. 41 It is also known that the same RyR2 mutation (e.g. A77V and R176Q) can lead to either CPVT or ARVD, 6 -8 suggesting the involvement of additional factors associated with fibrofatty replacement of the right ventricle. Indeed, it has been suggested that ARVD progression and disease expression are due to the complex effect of multiple genetic and/or epigenetic modifiers interacting with environmental factors such as exercise or inflammation. 49 In summary, we report on a novel molecular mechanism for the pathogenesis of ARVD2, which is likely to stimulate further investigations on RyR2 dysfunction in inherited and acquired cardiac pathologies. Our findings suggest that targeting defective RyR2 N-terminal intersubunit interactions represents a potentially effective therapy for the treatment of RyR2-related arrhythmogenic cardiac disease.
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